BlackRock Advisors LLC boosted its position in shares of PRA Health Sciences, Inc. (NASDAQ:PRAH) by 37.3% during the third quarter, Holdings Channel reports. The fund owned 58,830 shares of the company’s stock after buying an additional 15,970 shares during the period. BlackRock Advisors LLC owned approximately 0.10% of PRA Health Sciences worth $3,324,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. US Bancorp DE purchased a new position in shares of PRA Health Sciences during the third quarter worth approximately $106,000. BNP Paribas Arbitrage SA raised its position in shares of PRA Health Sciences by 120.5% in the third quarter. BNP Paribas Arbitrage SA now owns 2,093 shares of the company’s stock worth $118,000 after buying an additional 1,144 shares during the last quarter. BlackRock Inc. raised its position in shares of PRA Health Sciences by 26.0% in the second quarter. BlackRock Inc. now owns 2,399 shares of the company’s stock worth $100,000 after buying an additional 495 shares during the last quarter. Acrospire Investment Management LLC raised its position in shares of PRA Health Sciences by 8.7% in the second quarter. Acrospire Investment Management LLC now owns 2,500 shares of the company’s stock worth $104,000 after buying an additional 200 shares during the last quarter. Finally, Pacad Investment Ltd. purchased a new position in shares of PRA Health Sciences during the second quarter worth approximately $163,000. Institutional investors and hedge funds own 99.80% of the company’s stock.

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Shares of PRA Health Sciences, Inc. (NASDAQ:PRAH) opened at 57.59 on Friday. PRA Health Sciences, Inc. has a 12 month low of $35.60 and a 12 month high of $60.96. The firm has a 50-day moving average price of $54.72 and a 200-day moving average price of $51.48. The company has a market capitalization of $3.54 billion, a PE ratio of 44.71 and a beta of 0.53.

PRA Health Sciences (NASDAQ:PRAH) last issued its earnings results on Wednesday, November 2nd. The company reported $0.64 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.64. PRA Health Sciences had a return on equity of 21.25% and a net margin of 4.86%. The company earned $399.80 million during the quarter, compared to the consensus estimate of $394.87 million. During the same period in the previous year, the company posted $0.52 EPS. The firm’s revenue for the quarter was up 15.9% compared to the same quarter last year. On average, equities research analysts predict that PRA Health Sciences, Inc. will post $2.46 EPS for the current year.

WARNING: “BlackRock Advisors LLC Purchases 15,970 Shares of PRA Health Sciences, Inc. (PRAH)” was first posted by Daily Political and is owned by of Daily Political. If you are reading this article on another site, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at http://www.dailypolitical.com/2017/01/14/blackrock-advisors-llc-purchases-15970-shares-of-pra-health-sciences-inc-prah.html.

A number of brokerages recently commented on PRAH. Jefferies Group restated a “buy” rating and issued a $63.00 target price on shares of PRA Health Sciences in a research note on Saturday. KeyCorp restated a “buy” rating on shares of PRA Health Sciences in a research note on Friday, November 4th. Credit Suisse Group restated a “hold” rating and issued a $50.00 target price on shares of PRA Health Sciences in a research note on Thursday, November 3rd. Zacks Investment Research upgraded PRA Health Sciences from a “hold” rating to a “strong-buy” rating and set a $65.00 target price for the company in a research note on Wednesday, October 5th. Finally, Citigroup Inc. upped their target price on PRA Health Sciences from $55.00 to $66.00 and gave the company a “buy” rating in a research note on Thursday, September 22nd. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. PRA Health Sciences presently has a consensus rating of “Buy” and a consensus price target of $56.71.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

5 Day Chart for NASDAQ:PRAH

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences, Inc. (NASDAQ:PRAH).

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.